HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Capricor Therapeutics (NASDAQ:CAPR) and maintains a $40 price target.

May 14, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Capricor Therapeutics with a $40 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $40 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in CAPR's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100